Thermo Fisher Scientific has received the CE Mark in Europe to market and sell its rapid test for SARS-CoV-2, which causes the respiratory disease COVID-19.
The test utilizes Thermo Fisher's Applied Biosystems TaqPath assay and real-time polymerase chain reaction (PCR) technology to detect nucleic acid from SARS-CoV-2. Labs can use the test to process the results within four hours, including time for sample preparation and instrument analysis.
Thermo Fisher's test has also received approvals from the U.S., Canada, Singapore, India, Australia, and New Zealand. Furthermore, the company created an online resource for information related to the COVID-19 pandemic.